Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines

Journal of Controlled Release

Volumn 172, Issue 2, 2013, Pages 456-466

  Dobrovolskaia, Marina A ^a   McNeil, Scott E ^a  

^a SAIC FREDERICK INC   (United States)

Author keywords

Anaphylaxis; Coagulopathy; Complement activation; Cytokines; Disseminated intravascular coagulation; Hemolysis; Nanoparticles; Phagocytosis; Procoagulant activity; Thrombosis

Indexed keywords

ANAPHYLAXIS; COAGULOPATHY; COMPLEMENT ACTIVATIONS; CYTOKINES; HEMOLYSIS; INTRAVASCULAR; PHAGOCYTOSIS; THROMBOSIS;

ANTIGEN-ANTIBODY REACTIONS; CHARACTERIZATION; ENZYME INHIBITION; NANOPARTICLES; NANOSTRUCTURED MATERIALS; NANOTECHNOLOGY;

MEDICAL NANOTECHNOLOGY;

DOXORUBICIN; FULLERENE DERIVATIVE; INTERLEUKIN 1BETA; INTERLEUKIN 6; METAL NANOPARTICLE; MULTI WALLED NANOTUBE; PACLITAXEL; SILVER NANOPARTICLE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE;

ARTICLE; BIOCOMPATIBILITY; BLOOD CLOTTING TIME; CASE STUDY; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMICAL COMPOSITION; COLONY FORMING UNIT; COMPLEMENT ACTIVATION; CORRELATION ANALYSIS; DRUG HYPERSENSITIVITY; ERYTHROCYTE COUNT; HEMOLYSIS; HUMAN; HYDROPHOBICITY; IMMUNOASSAY; IMMUNOSTIMULATION; IMMUNOTOXICITY; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; NANOEMULSION; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; OPSONIZATION; PARTICLE SIZE; PERITONEUM MACROPHAGE; PHAGOCYTOSIS; PHYSICAL CHEMISTRY; PINOCYTOSIS; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; PROTEIN BINDING; STRUCTURE ACTIVITY RELATION; SURFACE CHARGE; SURFACE PROPERTY; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOGENICITY;

ANAPHYLAXIS; COAGULOPATHY; COMPLEMENT ACTIVATION; CYTOKINES; DISSEMINATED INTRAVASCULAR COAGULATION; HEMOLYSIS; NANOPARTICLES; PHAGOCYTOSIS; PROCOAGULANT ACTIVITY; THROMBOSIS;

ANIMALS; COMPLEMENT ACTIVATION; CYTOKINES; CYTOTOXICITY TESTS, IMMUNOLOGIC; DRUG EVALUATION, PRECLINICAL; HUMANS; NANOMEDICINE; NANOSTRUCTURES; PHAGOCYTOSIS; THROMBOSIS;

EID: 84887070003     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.05.025     Document Type: Article

References (116)

1. R. Medzhitov Origin and physiological roles of inflammation Nature 454 2008 428 435
2. R. Medzhitov, D.S. Schneider, and M.P. Soares Disease tolerance as a defense strategy Science 335 2012 936 941
3. R. Luebke Immunotoxicant screening and prioritization in the twenty-first century Toxicol. Pathol. 40 2012 294 299
4. J.H. Dean A brief history of immunotoxicology and a review of the pharmaceutical guidelines Int. J. Toxicol. 23 2004 83 90 (Pubitemid 38728936)
5. J. Descotes From clinical to human toxicology: linking animal research and risk assessment in man Toxicol. Lett. 140-141 2003 3 10 (Pubitemid 36378917)
6. R.A. Wilke, D.W. Lin, D.M. Roden, P.B. Watkins, D. Flockhart, I. Zineh, K.M. Giacomini, and R.M. Krauss Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges Nat. Rev. Drug Discov. 6 2007 904 916 (Pubitemid 350042398)
7. D.A. Smith, and E.F. Schmid Drug withdrawals and the lessons within Curr. Opin. Drug Discov. Devel. 9 2006 38 46 (Pubitemid 43099074)
8. D.K. Wysowski, and P. Nourjah Analyzing prescription drugs as causes of death on death certificates Public Health Rep. 119 2004 520 (Pubitemid 39468807)
9. D.K. Wysowski, and L. Swartz Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions Arch. Intern. Med. 165 2005 1363 1369 (Pubitemid 40973418)
10. CDER Guidance for Industry: Immunotoxicology Evaluation of Investigational New Drugs HHS 2001
11. J.H. Dean Issues with introducing new immunotoxicology methods into the safety assessment of pharmaceuticals Toxicology 119 1997 95 101 (Pubitemid 27144262)
12. D.R. Germolec, M. Kashon, A. Nyska, C.F. Kuper, C. Portier, C. Kommineni, K.A. Johnson, and M.I. Luster The accuracy of extended histopathology to detect immunotoxic chemicals Toxicol. Sci. 82 2004 504 514 (Pubitemid 39600078)
13. M.I. Luster, C. Portier, D.G. Pait, G.J. Rosenthal, D.R. Germolec, E. Corsini, B.L. Blaylock, P. Pollock, Y. Kouchi, W. Craig, K.L. White, A.E. Munson, and C.E. Comment Risk assessment in immunotoxicology. II. Relationships between immune and host resistance tests Fundam. Appl. Toxicol. 21 1993 71 82 (Pubitemid 23225987)
14. T.J. Woodruff, L. Zeise, D.A. Axelrad, K.Z. Guyton, S. Janssen, M. Miller, G.G. Miller, J.M. Schwartz, G. Alexeeff, H. Anderson, L. Birnbaum, F. Bois, V.J. Cogliano, K. Crofton, S.Y. Euling, P.M. Foster, D.R. Germolec, E. Gray, D.B. Hattis, A.D. Kyle, R.W. Luebke, M.I. Luster, C. Portier, D.C. Rice, G. Solomon, J. Vandenberg, and R.T. Zoeller Meeting report: moving upstream-evaluating adverse upstream end points for improved risk assessment and decision-making Environ. Health Perspect. 116 2008 1568 1575
15. D.R. Germolec, A. Nyska, M. Kashon, C.F. Kuper, C. Portier, C. Kommineni, K.A. Johnson, and M.I. Luster Extended histopathology in immunotoxicity testing: interlaboratory validation studies Toxicol. Sci. 78 2004 107 115 (Pubitemid 38351429)
16. M.A. Dobrovolskaia, D.R. Germolec, and J.L. Weaver Evaluation of nanoparticle immunotoxicity Nat. Nanotechnol. 4 2009 411 414
17. K. Tyner, and N. Sadrieh Considerations when submitting nanotherapeutics to FDA/CDER for regulatory review Methods Mol. Biol. 697 2011 17 31
18. S. Bancos, K.M. Tyner, and J.L. Weaver Immunotoxicity testing for drug-nanoparticle conjugates: regulatory considerations M.L. Yarmush, D. Shi, Frontiers in Nanobiomedical Research 2012 World Scientific Publishing Singapore
19. D. Boraschi, L. Costantino, and P. Italiani Interaction of nanoparticles with immunocompetent cells: nanosafety considerations Nanomedicine (Lond) 7 2012 121 131
20. M. Di Gioacchino, C. Petrarca, F. Lazzarin, L. Di Giampaolo, E. Sabbioni, P. Boscolo, R. Mariani-Costantini, and G. Bernardini Immunotoxicity of nanoparticles Int. J. Immunopathol. Pharmacol. 24 2011 65S 71S
21. M.A. Dobrovolskaia, and S.E. McNeil Immunological properties of engineered nanomaterials Nat. Nanotechnol. 2 2007 469 478 (Pubitemid 47220069)
22. S. Hussain, J.A. Vanoirbeek, and P.H. Hoet Interactions of nanomaterials with the immune system Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 4 2012 169 183
23. D. Izhaky, and I. Pecht What else can the immune system recognize? Proc. Natl. Acad. Sci. U. S. A. 95 1998 11509 11510 (Pubitemid 28460444)
24. S.M. Moghimi, and A.C. Hunter Capture of stealth nanoparticles by the body's defences Crit. Rev. Ther. Drug Carrier Syst. 18 2001 527 550 (Pubitemid 34024395)
25. S.M. Moghimi, L. Parhamifar, D. Ahmadvand, P.P. Wibroe, T.L. Andresen, Z.S. Farhangrazi, and A.C. Hunter Particulate systems for targeting of macrophages: basic and therapeutic concepts J. Innate Immun. 4 2012 509 528
26. J.J. Moon, B. Huang, and D.J. Irvine Engineering nano- and microparticles to tune immunity Adv. Mater. 24 2012 3724 3746
27. I. Pantic Nanoparticles and modulation of immune responses Sci. Prog. 94 2011 97 107
28. B. Rihova Immunomodulating activities of soluble synthetic polymer-bound drugs Adv. Drug Deliv. Rev. 54 2002 653 674 (Pubitemid 35247521)
29. J.M. Silva, M. Videira, R. Gaspar, V. Preat, and H.F. Florindo Immune system targeting by biodegradable nanoparticles for cancer vaccines J. Control. Release 168 2 2013 179 199
30. W. Caron, S. Rawal, G. Song, P. Kumar, L. J.C., and Z. W.C. Bidirectional interaction between nanoparticles and cells of the mononuclear phagocyte system M.L. Yarmush, D. Shi, Frontiers in Nanobiomedical Research 2012 World Scientific Publishing Singapore
31. M.A. Dobrovolskaia, and S.E. McNeil Immunological properties of engineered nanomaterials: introduction M.L. Yarmush, D. Shi, Frontiers in Nanobiomedical Research 2012 World Scientific Publishing Singapore
32. L. Treuel, and G.U. Nienhaus Nanoparticle interaction with plasma proteins as it relates to biodistribution M.L. Yarmush, D. Shi, Frontiers in Nanobiomedical Research 2012 World Scientific Publishing Singapore
33. B. Fadeel Clear and present danger? Engineered nanoparticles and the immune system Swiss Med. Wkly. 142 2012 w13609
34. E. Mahon, A. Salvati, F. Baldelli Bombelli, I. Lynch, and K.A. Dawson Designing the nanoparticle-biomolecule interface for "targeting and therapeutic delivery" J. Control. Release 161 2012 164 174
35. A.M. Nystrom, and B. Fadeel Safety assessment of nanomaterials: implications for nanomedicine J. Control. Release 161 2012 403 408
36. M.A. Dobrovolskaia, and S.E. McNeil In vitro assays for monitoring nanoparticle interaction with components of the immune system M.L. Yarmush, D. Shi, Frontiers in Nanobiomedical Research 2012 World Scientific Publishing Singapore
37. G. Oberdorster, A. Maynard, K. Donaldson, V. Castranova, J. Fitzpatrick, K. Ausman, J. Carter, B. Karn, W. Kreyling, D. Lai, S. Olin, N. Monteiro-Riviere, D. Warheit, and H. Yang Principles for characterizing the potential human health effects from exposure to nanomaterials: elements of a screening strategy Part. Fibre Toxicol. 2 2005 8
38. T. Hartung, and E. Sabbioni Alternative in vitro assays in nanomaterial toxicology Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2011 (July 15, Electronic publication ahead of print)
39. CDER Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers 2005
40. S. Lu, R. Duffin, C. Poland, P. Daly, F. Murphy, E. Drost, W. Macnee, V. Stone, and K. Donaldson Efficacy of simple short-term in vitro assays for predicting the potential of metal oxide nanoparticles to cause pulmonary inflammation Environ. Health Perspect. 117 2009 241 247
41. Y. Li, J. Liu, Y. Zhong, J. Zhang, Z. Wang, L. Wang, Y. An, M. Lin, Z. Gao, and D. Zhang Biocompatibility of Fe(3)O(4)@Au composite magnetic nanoparticles in vitro and in vivo Int. J. Nanomedicine 6 2011 2805 2819
42. H.B. Agashe, T. Dutta, M. Garg, and N.K. Jain Investigations on the toxicological profile of functionalized fifth-generation poly (propylene imine) dendrimer J. Pharm. Pharmacol. 58 2006 1491 1498 (Pubitemid 44785538)
43. D. Bhadra, A.K. Yadav, S. Bhadra, and N.K. Jain Glycodendrimeric nanoparticulate carriers of primaquine phosphate for liver targeting Int. J. Pharm. 295 2005 221 233 (Pubitemid 40558805)
44. A. Asthana, A.S. Chauhan, P.V. Diwan, and N.K. Jain Poly(amidoamine) (PAMAM) dendritic nanostructures for controlled site-specific delivery of acidic anti-inflammatory active ingredient AAPS PharmSciTech 6 2005 E536 E542
45. D. Bhadra, S. Bhadra, S. Jain, and N.K. Jain A PEGylated dendritic nanoparticulate carrier of fluorouracil Int. J. Pharm. 257 2003 111 124 (Pubitemid 36507038)
46. N. Malik, R. Wiwattanapatapee, R. Klopsch, K. Lorenz, H. Frey, J.W. Weener, E.W. Meijer, W. Paulus, and R. Duncan Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo J. Control. Release 65 2000 133 148 (Pubitemid 30122922)
47. P. Agrawal, U. Gupta, and N.K. Jain Glycoconjugated peptide dendrimers-based nanoparticulate system for the delivery of chloroquine phosphate Biomaterials 28 2007 3349 3359 (Pubitemid 46693974)
48. B. Wildt, R.A. Malinauskas, and R.P. Brown Effects of nanomaterials on erythrocytes M.L. Yarmush, D. Shi, Frontiers in Nanobiomedical Research 2012 World Scientific Publishing Singapore
49. A.I.S.m. E2425 Standard Test Method for Analysis of Hemolytic Properties of Nanoparticles ASTM International 2008
50. M.A. Dobrovolskaia, J.D. Clogston, B.W. Neun, J.B. Hall, A.K. Patri, and S.E. McNeil Method for analysis of nanoparticle hemolytic properties in vitro Nano Lett. 8 2008 2180 2187
51. R.M. Crist, J.H. Grossman, A.K. Patri, S.T. Stern, M.A. Dobrovolskaia, P.P. Adiseshaiah, J.D. Clogston, and S.E. McNeil Common pitfalls in nanotechnology: lessons learned from NCI's Nanotechnology Characterization Laboratory Integr. Biol. (Camb) 5 1 2013 66 73
52. O.M. Merkel, R. Urbanics, P. Bedocs, Z. Rozsnyay, L. Rosivall, M. Toth, T. Kissel, and J. Szebeni In vitro and in vivo complement activation and related anaphylactic effects associated with polyethylenimine and polyethylenimine- graft-poly(ethylene glycol) block copolymers Biomaterials 32 2011 4936 4942
53. J. Szebeni, C.R. Alving, L. Rosivall, R. Bunger, L. Baranyi, P. Bedocs, M. Toth, and Y. Barenholz Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles J. Liposome Res. 17 2007 107 117 (Pubitemid 47026981)
54. B.W. Neun, and M.A. Dobrovolskaia Qualitative analysis of total complement activation by nanoparticles Methods Mol. Biol. 697 2011 237 245
55. C.T. Pham, L.M. Mitchell, J.L. Huang, C.M. Lubniewski, O.F. Schall, J.K. Killgore, D. Pan, S.A. Wickline, G.M. Lanza, and D.E. Hourcade Variable antibody-dependent activation of complement by functionalized phospholipid nanoparticle surfaces J. Biol. Chem. 286 2011 123 130
56. E. Allard-Vannier, S. Cohen-Jonathan, J. Gautier, K. Herve-Aubert, E. Munnier, M. Souce, P. Legras, C. Passirani, and I. Chourpa Pegylated magnetic nanocarriers for doxorubicin delivery: a quantitative determination of stealthiness in vitro and in vivo Eur. J. Pharm. Biopharm. 81 2012 498 505
57. N.T. Huynh, M. Morille, J. Bejaud, P. Legras, A. Vessieres, G. Jaouen, J.P. Benoit, and C. Passirani Treatment of 9 L gliosarcoma in rats by ferrociphenol-loaded lipid nanocapsules based on a passive targeting strategy via the EPR effect Pharm. Res. 28 2011 3189 3198
58. X. Shan, Y. Yuan, C. Liu, X. Tao, Y. Sheng, and F. Xu Influence of PEG chain on the complement activation suppression and longevity in vivo prolongation of the PCL biomedical nanoparticles Biomed. Microdevices 11 2009 1187 1194
59. A. Chanan-Khan, J. Szebeni, S. Savay, L. Liebes, N.M. Rafique, C.R. Alving, and F.M. Muggia Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions Ann. Oncol. 14 2003 1430 1437 (Pubitemid 37185291)
60. J. Szebeni, P. Bedocs, Z. Rozsnyay, Z. Weiszhar, R. Urbanics, L. Rosivall, R. Cohen, O. Garbuzenko, G. Bathori, M. Toth, R. Bunger, and Y. Barenholz Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and Am Bisome Nanomedicine 8 2012 176 184
61. J. Szebeni, P. Bedocs, R. Urbanics, R. Bunger, L. Rosivall, M. Toth, and Y. Barenholz Prevention of infusion reactions to PEGylated liposomal doxorubicin via tachyphylaxis induction by placebo vesicles: a porcine model J. Control. Release 160 2012 382 387
62. J. Szebeni, F. Muggia, A. Gabizon, and Y. Barenholz Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention Adv. Drug Deliv. Rev. 63 2011 1020 1030
63. C. Salvador-Morales, and R. Sims Complement activation M.L. Yarmush, D. Shi, Frontiers in Nanobiomedical Research 2012 World Scientific Publishing Singapore
64. A. Batista-Duharte, E.B. Lindblad, and E. Oviedo-Orta Progress in understanding adjuvant immunotoxicity mechanisms Toxicol. Lett. 203 2011 97 105
65. F.R. Brennan, L.D. Morton, S. Spindeldreher, A. Kiessling, R. Allenspach, A. Hey, P.Y. Muller, W. Frings, and J. Sims Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies MAbs 2 2010 233 255
66. J. Descotes, and A. Gouraud Clinical immunotoxicity of therapeutic proteins Expert Opin. Drug Metab. Toxicol. 4 2008 1537 1549
67. P. Duramad, I.B. Tager, and N.T. Holland Cytokines and other immunological biomarkers in children's environmental health studies Toxicol. Lett. 172 2007 48 59 (Pubitemid 47126222)
68. S.D. Xiang, M. Fuchsberger, T.D.L. Karlson, C.L. Hardy, C. Selomulya, and M. Plebanski Nanoparticles, immune modulation and vaccine delivery M.L. Yarmush, D. Shi, Frontiers in Nanobiomedical Research 2012 World Scientific Publishing Singapore
69. D.F. Moyano, M. Goldsmith, D.J. Solfiell, D. Landesman-Milo, O.R. Miranda, D. Peer, and V.M. Rotello Nanoparticle hydrophobicity dictates immune response J. Am. Chem. Soc. 134 2012 3965 3967
70. R.S. Geary, R.Z. Yu, T. Watanabe, S.P. Henry, G.E. Hardee, A. Chappell, J. Matson, H. Sasmor, L. Cummins, and A.A. Levin Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2′-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species Drug Metab. Dispos. 31 2003 1419 1428 (Pubitemid 37310332)
71. S.P. Henry, G. Beattie, G. Yeh, A. Chappel, P. Giclas, A. Mortari, M.A. Jagels, D.J. Kornbrust, and A.A. Levin Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide Int. Immunopharmacol. 2 2002 1657 1666 (Pubitemid 35284605)
72. J.J. Senn, S. Burel, and S.P. Henry Non-CpG-containing antisense 2′-methoxyethyl oligonucleotides activate a proinflammatory response independent of Toll-like receptor 9 or myeloid differentiation factor 88 J. Pharmacol. Exp. Ther. 314 2005 972 979 (Pubitemid 41205959)
73. M. Daneshian, S. von Aulock, and T. Hartung Assessment of pyrogenic contaminations with validated human whole-blood assay Nat. Protoc. 4 2009 1709 1721
74. M. Daneshian, A. Wendel, T. Hartung, and S. von Aulock High sensitivity pyrogen testing in water and dialysis solutions J. Immunol. Methods 336 2008 64 70
75. I. Langezaal, S. Coecke, and T. Hartung Whole blood cytokine response as a measure of immunotoxicity Toxicol. In Vitro 15 2001 313 318 (Pubitemid 32889650)
76. S. Schindler, S. von Aulock, M. Daneshian, and T. Hartung Development, validation and applications of the monocyte activation test for pyrogens based on human whole blood ALTEX 26 2009 265 277
77. M.A. Dobrovolskaia, and S.E. McNeil Nanoparticles and endotoxin M.L. Yarmush, D. Shi, Frontiers in Nanobiomedical Research 2012 World Scientific Publishing Singapore
78. A. Franca, P. Aggarwal, E.V. Barsov, S.V. Kozlov, M.A. Dobrovolskaia, and A. Gonzalez-Fernandez Macrophage scavenger receptor A mediates the uptake of gold colloids by macrophages in vitro Nanomedicine (Lond) 6 2011 1175 1188
79. M. Geiser Update on macrophage clearance of inhaled micro- and nanoparticles J. Aerosol Med. Pulm. Drug Deliv. 23 2010 207 217
80. S. Kanno, A. Furuyama, and S. Hirano A murine scavenger receptor MARCO recognizes polystyrene nanoparticles Toxicol. Sci. 97 2007 398 406 (Pubitemid 47073855)
81. D.M. Underhill, and H.S. Goodridge Information processing during phagocytosis Nat. Rev. Immunol. 12 2012 492 502
82. M.P. Monopoli, D. Walczyk, A. Campbell, G. Elia, I. Lynch, F.B. Bombelli, and K.A. Dawson Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles J. Am. Chem. Soc. 133 2011 2525 2534
83. G. Gaucher, K. Asahina, J. Wang, and J.C. Leroux Effect of poly(N-vinyl-pyrrolidone)-block-poly(d,l-lactide) as coating agent on the opsonization, phagocytosis, and pharmacokinetics of biodegradable nanoparticles Biomacromolecules 10 2009 408 416
84. M. Roser, D. Fischer, and T. Kissel Surface-modified biodegradable albumin nano- and microspheres. II: effect of surface charges on in vitro phagocytosis and biodistribution in rats Eur. J. Pharm. Biopharm. 46 1998 255 263 (Pubitemid 29057671)
85. M. Demoy, J.P. Andreux, C. Weingarten, B. Gouritin, V. Guilloux, and P. Couvreur In vitro evaluation of nanoparticles spleen capture Life Sci. 64 1999 1329 1337 (Pubitemid 29156861)
86. G.F. Paciotti, L. Myer, D. Weinreich, D. Goia, N. Pavel, R.E. McLaughlin, and L. Tamarkin Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery Drug Deliv. 11 2004 169 183 (Pubitemid 38720414)
87. P.P. Adiseshaiah, J.B. Hall, and S.E. McNeil Nanomaterial standards for efficacy and toxicity assessment Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2 2010 99 112
88. J. Myerson, L. He, G. Lanza, D. Tollefsen, and S. Wickline Thrombin-inhibiting perfluorocarbon nanoparticles provide a novel strategy for the treatment and magnetic resonance imaging of acute thrombosis J. Thromb. Haemost. 9 2011 1292 1300
89. H. Nabeshi, T. Yoshikawa, K. Matsuyama, Y. Nakazato, A. Arimori, M. Isobe, S. Tochigi, S. Kondoh, T. Hirai, T. Akase, T. Yamashita, K. Yamashita, T. Yoshida, K. Nagano, Y. Abe, Y. Yoshioka, H. Kamada, T. Imazawa, N. Itoh, M. Kondoh, K. Yagi, T. Mayumi, S. Tsunoda, and Y. Tsutsumi Amorphous nanosilicas induce consumptive coagulopathy after systemic exposure Nanotechnology 23 2012 045101
90. D. Simberg, W.M. Zhang, S. Merkulov, K. McCrae, J.H. Park, M.J. Sailor, and E. Ruoslahti Contact activation of kallikrein-kinin system by superparamagnetic iron oxide nanoparticles in vitro and in vivo J. Control. Release 140 2009 301 305
91. J. Laloy, S. Robert, C. Marbehant, F. Mullier, J. Mejia, J.P. Piret, S. Lucas, B. Chatelain, J.M. Dogne, O. Toussaint, B. Masereel, and S. Rolin Validation of the calibrated thrombin generation test (cTGT) as the reference assay to evaluate the procoagulant activity of nanomaterials Nanotoxicology 6 2012 213 232
92. A. Radomski, P. Jurasz, D. Alonso-Escolano, M. Drews, M. Morandi, T. Malinski, and M.W. Radomski Nanoparticle-induced platelet aggregation and vascular thrombosis Br. J. Pharmacol. 146 2005 882 893 (Pubitemid 41622255)
93. J. Geys, A. Nemmar, E. Verbeken, E. Smolders, M. Ratoi, M.F. Hoylaerts, B. Nemery, and P.H. Hoet Acute toxicity and prothrombotic effects of quantum dots: impact of surface charge Environ. Health Perspect. 116 2008 1607 1613
94. P. Bihari, M. Holzer, M. Praetner, J. Fent, M. Lerchenberger, C.A. Reichel, M. Rehberg, S. Lakatos, and F. Krombach Single-walled carbon nanotubes activate platelets and accelerate thrombus formation in the microcirculation Toxicology 269 2010 148 154
95. E.A. Jun, K.M. Lim, K. Kim, O.N. Bae, J.Y. Noh, K.H. Chung, and J.H. Chung Silver nanoparticles enhance thrombus formation through increased platelet aggregation and procoagulant activity Nanotoxicology 5 2011 157 167
96. K. Greish, G. Thiagarajan, H. Herd, R. Price, H. Bauer, D. Hubbard, A. Burckle, S. Sadekar, T. Yu, A. Anwar, A. Ray, and H. Ghandehari Size and surface charge significantly influence the toxicity of silica and dendritic nanoparticles Nanotoxicology 6 2012 713 723
97. M.A. Dobrovolskaia, A.K. Patri, T.M. Potter, J.C. Rodriguez, J.B. Hall, and S.E. McNeil Dendrimer-induced leukocyte procoagulant activity depends on particle size and surface charge Nanomedicine (Lond) 7 2012 245 256
98. M.A. Dobrovolskaia, A.K. Patri, J. Simak, J.B. Hall, J. Semberova, S.H. De Paoli Lacerda, and S.E. McNeil Nanoparticle size and surface charge determine effects of PAMAM dendrimers on human platelets in vitro Mol. Pharm. 9 2012 382 393
99. C.F. Jones, R.A. Campbell, A.E. Brooks, S. Assemi, S. Tadjiki, G. Thiagarajan, C. Mulcock, A.S. Weyrich, B.D. Brooks, H. Ghandehari, and D.W. Grainger Cationic PAMAM dendrimers aggressively initiate blood clot formation ACS Nano 6 11 2012 9900 9910
100. C.F. Jones, R.A. Campbell, Z. Franks, C.C. Gibson, G. Thiagarajan, A. Vieira-de-Abreu, S. Sukavaneshvar, S.F. Mohammad, D.Y. Li, H. Ghandehari, A.S. Weyrich, B.D. Brooks, and D.W. Grainger Cationic PAMAM dendrimers disrupt key platelet functions Mol. Pharm. 9 2012 1599 1611
101. E.Y. Moon, G.H. Yi, J.S. Kang, J.S. Lim, H.M. Kim, and S. Pyo An increase in mouse tumor growth by an in vivo immunomodulating effect of titanium dioxide nanoparticles J. Immunotoxicol. 8 2011 56 67
102. R.E. Parchment, M. Gordon, C.K. Grieshaber, C. Sessa, D. Volpe, and M. Ghielmini Predicting hematological toxicity (myelosuppression) of cytotoxic drug therapy from in vitro tests Ann. Oncol. 9 1998 357 364 (Pubitemid 28273026)
103. H.P. Behrsing, M.J. Furniss, K.A. Robillard, J.E. Tomaszewski, and R.E. Parchment In vitro comparison of O4-benzylfolate modulated, BCNU-induced toxicity in human bone marrow using CFU-GM and tumor cell lines Cancer Chemother. Pharmacol. 65 2010 1083 1091
104. C.L. Erickson-Miller, R.D. May, J. Tomaszewski, B. Osborn, M.J. Murphy, J.G. Page, and R.E. Parchment Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro Cancer Chemother. Pharmacol. 39 1997 467 472 (Pubitemid 27078134)
105. A. Pessina, B. Albella, M. Bayo, J. Bueren, P. Brantom, S. Casati, C. Croera, R. Parchment, D. Parent-Massin, G. Schoeters, Y. Sibiri, R. Van Den Heuvel, and L. Gribaldo In vitro tests for haematotoxicity: prediction of drug-induced myelosuppression by the CFU-GM assay Altern. Lab. Anim. 30 Suppl. 2 2002 75 79 (Pubitemid 36168716)
106. A. Pessina, B. Albella, J. Bueren, P. Brantom, S. Casati, L. Gribaldo, C. Croera, G. Gagliardi, P. Foti, R. Parchment, D. Parent-Massin, Y. Sibiril, and R. Van Den Heuvel Prevalidation of a model for predicting acute neutropenia by colony forming unit granulocyte/macrophage (CFU-GM) assay Toxicol. In Vitro 15 2001 729 740 (Pubitemid 33043962)
107. A. Pessina, A. Bonomi, L. Cavicchini, B. Albella, L. Cerrato, D. Parent-Massin, Y. Sibiril, R. Parchment, H. Behrsing, P. Verderio, S. Pizzamiglio, M. Giangreco, C. Baglio, V. Cocce, F. Sisto, and L. Gribaldo Prevalidation of the rat CFU-GM assay for in vitro toxicology applications Altern. Lab. Anim. 38 2010 105 117
108. D. Moneta, C. Geroni, O. Valota, P. Grossi, M.J. de Jonge, M. Brughera, E. Colajori, M. Ghielmini, and C. Sessa Predicting the maximum-tolerated dose of PNU-159548 (4-demethoxy-3′-deamino-3′-aziridinyl-4′- methylsulphonyl-daunorubicin) in humans using CFU-GM clonogenic assays and prospective validation Eur. J. Cancer 39 2003 675 683 (Pubitemid 36287381)
109. N. Masubuchi, R.D. May, and R. Atsumi A predictive model of human myelotoxicity using five camptothecin derivatives and the in vitro colony-forming unit granulocyte/macrophage assay Clin. Cancer Res. 10 2004 6722 6731 (Pubitemid 39346570)
110. S.G. Gomez, J.A. Bueren, G. Faircloth, and B. Albella Use of CFU-GM assay for prediction of human maximum tolerated dose of a new antitumoral drug: Yondelis (ET-743) Toxicol. In Vitro 17 2003 671 674 (Pubitemid 37352677)
111. A. Pessina, B. Albella, M. Bayo, J. Bueren, P. Brantom, S. Casati, C. Croera, G. Gagliardi, P. Foti, R. Parchment, D. Parent-Massin, G. Schoeters, Y. Sibiril, R. Van Den Heuvel, and L. Gribaldo Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics Toxicol. Sci. 75 2003 355 367 (Pubitemid 37220283)
112. L. Bregoli, F. Chiarini, A. Gambarelli, G. Sighinolfi, A.M. Gatti, P. Santi, A.M. Martelli, and L. Cocco Toxicity of antimony trioxide nanoparticles on human hematopoietic progenitor cells and comparison to cell lines Toxicology 262 2009 121 129
113. S. Gibaud, J.P. Andreux, C. Weingarten, M. Renard, and P. Couvreur Increased bone marrow toxicity of doxorubicin bound to nanoparticles Eur. J. Cancer 30A 1994 820 826 (Pubitemid 24217340)
114. D.Y. Zhang, X.Z. Shen, J.Y. Wang, L. Dong, Y.L. Zheng, and L.L. Wu Preparation of chitosan-polyaspartic acid-5-fluorouracil nanoparticles and its anti-carcinoma effect on tumor growth in nude mice World J. Gastroenterol. 14 2008 3554 3562
115. H. Gao, J.Y. Wang, X.Z. Shen, Y.H. Deng, and W. Zhang Preparation of magnetic polybutylcyanoacrylate nanospheres encapsulated with aclacinomycin A and its effect on gastric tumor World J. Gastroenterol. 10 2004 2010 2013 (Pubitemid 39106948)
116. B.S. Zolnik, A. Gonzalez-Fernandez, N. Sadrieh, and M.A. Dobrovolskaia Nanoparticles and the immune system Endocrinology 151 2010 458 465